Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the chances of curing the cancer and make the patients live longer without the cancer getting worse. The main questions we want to answer in this study are: - Can using relugolix and enzalutamide together help increase the chances of curing high-risk advanced prostate cancer? - Does this combination treatment help patients live longer without their cancer getting worse? Participants in this study will be asked to take relugolix and enzalutamide as part of their cancer treatment. They will also undergo Radiation Therapy or prostatectomy, which are standard treatments for this type of cancer.


Clinical Trial Description

This clinical trial aims to assess the effectiveness and safety of combining relugolix and enzalutamide as neoadjuvant and adjuvant androgen deprivation therapy (ADT) in patients diagnosed with high-risk locally advanced prostate cancer who are also candidates for definitive radiation therapy (RT) or surgical treatment. The objectives of this phase Ib clinical trial are to evaluate the efficacy, safety, and dynamic changes in biomarkers associated with this combination therapy. A combined total of up to 41 evaluable patients will participate in this study, with the initial safety lead-in cohorts involving a potential enrollment of 12 patients, followed by a dose expansion cohort that may include up to 29 subjects. The combined treatment cycle spans 28 days, with patients receiving six months of neoadjuvant therapy followed by an additional 18 months in the adjuvant setting. Treatment duration may be shortened if unacceptable toxicity occurs or if a patient withdraws consent. Approximately 24 months of post-accrual follow-up are anticipated to adequately assess the efficacy and safety of the treatment. Ultimately, the study aims to contribute valuable insights into the potential benefits of neoadjuvant and adjuvant hormonal therapy with relugolix plus enzalutamide in improving outcomes for patients facing high-risk locally advanced prostate cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06130995
Study type Interventional
Source University of Oklahoma
Contact lead onco nurse, RN
Phone 405-271-8777
Email SCCIITOffice@ouhsc.edu
Status Not yet recruiting
Phase Phase 1
Start date August 2024
Completion date April 2030

See also
  Status Clinical Trial Phase
Terminated NCT03440879 - Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose N/A
Recruiting NCT05700903 - Contributions to Hypertension With Androgen Deprivation Therapy Phase 4
Completed NCT01711892 - Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy N/A
Recruiting NCT05781217 - Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624 Phase 3
Active, not recruiting NCT04062162 - Walking Football as a Supportive Medicine for Patients With Prostate Cancer N/A
Recruiting NCT03845751 - EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control. Phase 2
Active, not recruiting NCT03867357 - Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia
Completed NCT02631681 - Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy N/A
Recruiting NCT00957606 - Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer Phase 3
Recruiting NCT05327465 - Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy N/A
Completed NCT04500080 - Feasibility and Safety of Physical Exercise in Men With Prostate Cancer N/A
Completed NCT03672396 - Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer N/A